Comparing two types of vaginal brachytherapy for endometrial cancer
A Randomized Phase III Trial of Two Standard Dose Fractionation Regimes for Adjuvant Vaginal Brachytherapy in Early Stage Endometrial Cancer
This study is testing two types of radiation treatments for early-stage endometrial cancer to see which one has a better impact on sexual health after surgery.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 258 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University of Virginia Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 3 sites (Baltimore, Maryland and 2 other locations) |
| Trial ID | NCT03785288 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effects of two different standard treatments for early-stage endometrial cancer on sexual dysfunction. Patients will be randomized to receive either high dose radiation vaginal brachytherapy in three fractions of 7 Gy or in six fractions of 4 Gy, administered 4-12 weeks post-surgery. Participants will also have the option to switch to the alternate treatment if they prefer. Follow-up assessments will be conducted at 3 months, 1 year, and 2 years to monitor outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with FIGO Stage I-II endometrioid cancer who have undergone a total abdominal or laparoscopic hysterectomy.
Not a fit: Patients with advanced stage endometrial cancer (FIGO stage III-IV) or those requiring additional pelvic radiation therapy or chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment options and quality of life for patients with endometrial cancer by addressing sexual dysfunction.
How similar studies have performed: Other studies have shown promising results with similar brachytherapy approaches, indicating potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Willingness and ability to provide written informed consent and to comply with the study protocol as judged by the investigator. * Surgery consisted of Total Abdominal or Laparoscopic Hysterectomy and Bilateral Salpingo Oophorectomy (TH-BSO) with or without lymph node dissection. * Subject must have FIGO Stage I-II (grade 1-3) pathologically proven (histologic) endometrioid cancer, including all subtypes. Serous, clear cell, and carcinosarcoma histologic pathologies are allowed. * Subjects must have no measurable disease after surgery. * ECOG Performance Status of 0-2 * Age ≥ 18 years * Subject must have a life expectancy ≥ 12 months Exclusion Criteria: * Disease of more advanced stage (FIGO stage III-IV) or disease for which adjuvant external beam radiation therapy or chemotherapy is indicated * Patients with a history of prior pelvic radiation therapy or if additional pelvic radiation therapy is planned * Subjects who have not recovered from side effects of agents administered more than 4 weeks prior to the on-study date * Subjects that require \> 14 weeks between surgery and initiation of radiation therapy on study unless the subject is receiving chemotherapy. Subjects receiving chemotherapy may have radiation therapy initiated within 6 months after surgery. \* Subjects who do not meet this criteria may still be eligible. The UVA Coordinating Center and Overall Study PI will review each case and inform the site of the approval decision. * Subjects who are receiving any investigational agents or have had any investigational agent within the 30 days prior to the on-study date * Subject is unable or unwilling to participate in a study-related procedure * Pregnant and breastfeeding women are excluded from this study * Subject is a prisoner * A serious uncontrolled medical disorder that in the opinion of the Investigator would impair the ability of the subject to receive protocol therapy. * Subjects with a history of evidence upon physical examination of central nervous system disease including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (stroke), transient ischemic attack, or subarachnoid hemorrhage within six months of study entry
Where this trial is running
Baltimore, Maryland and 2 other locations
- University of Maryland Medical Center (UMMC) — Baltimore, Maryland, United States (Recruiting)
- SUNY Upstate Medical University — Syracuse, New York, United States (Recruiting)
- University of Virginia — Charlottesville, Virginia, United States (Recruiting)
Study contacts
- Principal investigator: Kara Romano, MD — University of Virginia
- Study coordinator: Song Wood
- Email: UVARADONCClinicalTrials@uvahealth.org
- Phone: 434-243-0008
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.